TITLE

494 Levosimendan, compared to dobutamine, reduces mortality in patients with a history of heart failure

AUTHOR(S)
Cohen-Solal, A.; Mebazaa, A.; Thakkar, R.; Schulz, G.; Huang, B.; Padley, R.J.
PUB. DATE
June 2007
SOURCE
European Journal of Heart Failure. Supplements;
SOURCE TYPE
DOC. TYPE
Abstract
ABSTRACT
The article presents a study which evaluated the effects of the potassium channel-adenosine triphosphate (K+-ATP) channel opener, levosimendan, and dobutamine on all-case mortality (ACM) in patients with or without a history of heart failure (hxHF).
ACCESSION #
25768435

 

Related Articles

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics